Clinical Trial Update: Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib [Phase 3]

View source ↗

Summary

A randomized phase III trial compared imatinib dose optimization versus nilotinib in chronic myeloid leukemia patients with suboptimal response to imatinib; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2015-11-16